Interactions of Homocysteine, Nitric Oxide, Folate and Radicals in the Progressively Damaged Endothelium
暂无分享,去创建一个
[1] M Yokoyama,et al. Taurine Prevents the Decrease in Expression and Secretion of Extracellular Superoxide Dismutase Induced by Homocysteine: Amelioration of Homocysteine-Induced Endoplasmic Reticulum Stress by Taurine , 2001, Circulation.
[2] N. Fink,et al. Dietary supplement with vitamin C prevents nitrate tolerance. , 1998, The Journal of clinical investigation.
[3] H. Knapp,et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. , 2001, Clinical science.
[4] O. Stanger. Physiology of folic acid in health and disease. , 2002, Current drug metabolism.
[5] J. Kooner,et al. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[6] J S Beckman,et al. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.
[7] L. Viinikka,et al. Nitric oxide as a challenge for the clinical chemistry laboratory. , 1996, Scandinavian journal of clinical and laboratory investigation.
[8] Yuan-Yuan Shi,et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. , 2001, The Journal of clinical investigation.
[9] J. Finkelstein,et al. Methionine metabolism in mammals. , 1990, The Journal of nutritional biochemistry.
[10] E. Werner,et al. l-Ascorbic Acid Potentiates Endothelial Nitric Oxide Synthesis via a Chemical Stabilization of Tetrahydrobiopterin* , 2001, The Journal of Biological Chemistry.
[11] S. Verma,et al. Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction , 2003, Molecular and Cellular Biochemistry.
[12] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[13] J. Loscalzo. Folate and nitrate-induced endothelial dysfunction: a simple treatment for a complex pathobiology. , 2001, Circulation.
[14] A. Castaigne,et al. Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. , 1992, The American journal of cardiology.
[15] S. Moncada,et al. Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis , 1992, Journal of cardiovascular pharmacology.
[16] J. Zweier,et al. Superoxide Generation from Endothelial Nitric-oxide Synthase , 1998, The Journal of Biological Chemistry.
[17] T. Wascher,et al. Effects of Folate Treatment and Homocysteine Lowering on Resistance Vessel Reactivity in Atherosclerotic Subjects , 2002, Journal of Pharmacology and Experimental Therapeutics.
[18] D. Stuehr. Structure-function aspects in the nitric oxide synthases. , 1997, Annual review of pharmacology and toxicology.
[19] T. Rabelink,et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. , 2000, Circulation research.
[20] Amir Lerman,et al. Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[21] B. Mayer,et al. Thiols and neuronal nitric oxide synthase: complex formation, competitive inhibition, and enzyme stabilization. , 1997, Biochemistry.
[22] Z. Ungvari,et al. Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: morphological and functional evidence for increased peroxynitrite formation. , 2002, The American journal of pathology.
[23] T. Oury,et al. Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[24] V. Hinsbergh. NO or H(2)O(2) for endothelium-dependent vasorelaxation: Tetrahydrobiopterin makes the difference. , 2001 .
[25] Z. Ungvari,et al. Xanthine Oxidase‐Derived Reactive Oxygen Species Convert Flow‐Induced Arteriolar Dilation to Constriction in Hyperhomocysteinemia Possible Role of Peroxynitrite , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[26] D. Remick,et al. Homocysteine Mediated Expression and Secretion of Monocyte Chemoattractant Protein-1 and Interleukin-8 in Human Monocytes , 2003, Circulation research.
[27] R K Gordon,et al. S‐Adenosylmetliionine and methylation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] T. Rabelink,et al. Influence of folic acid on postprandial endothelial dysfunction. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[29] P. Libby,et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.
[30] M Yamamoto,et al. Effects of homocysteine on the binding of extracellular‐superoxide dismutase to the endothelial cell surface , 2000, FEBS letters.
[31] H. Knapp,et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. , 1999, Circulation.
[32] W E Haefeli,et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.
[33] HidemiNonaka,et al. Taurine Prevents the Decrease in Expression and Secretion of Extracellular Superoxide Dismutase Induced by Homocysteine , 2001 .
[34] Y. Hattori,et al. HMG-CoA Reductase Inhibitor Increases GTP Cyclohydrolase I mRNA and Tetrahydrobiopterin in Vascular Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[35] M. Nakamura,et al. The cardiovascular effects and implications of peroxynitrite. , 1999, Cardiovascular research.
[36] K. Channon,et al. Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.
[37] T. Gori,et al. Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction and Nitrate Tolerance: A Human In Vivo Study , 2001, Circulation.
[38] S. Verma,et al. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. , 2002, American journal of physiology. Heart and circulatory physiology.
[39] R. Furchgott,et al. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.
[40] V. Hinsbergh. NO or H2O2 for Endothelium-Dependent Vasorelaxation , 2001 .
[41] Jonathan Goodfellow,et al. Folic Acid Improves Endothelial Function in Coronary Artery Disease via Mechanisms Largely Independent of Homocysteine Lowering , 2002, Circulation.
[42] A. Yeung,et al. Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.
[43] E. Werner,et al. In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.
[44] W. Koppenol,et al. The basic chemistry of nitrogen monoxide and peroxynitrite. , 1998, Free radical biology & medicine.
[45] D. Kennedy,et al. Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs. , 1997, Atherosclerosis.
[46] Y. T. Lee,et al. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. , 2000, Circulation.
[47] J. Genest,et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. , 2000, Journal of the American College of Cardiology.
[48] C. Maxwell,et al. Serum Folate Levels and Subsequent Adverse Cerebrovascular Outcomes in Elderly Persons , 2002, Dementia and Geriatric Cognitive Disorders.
[49] G. Omenn,et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.
[50] T. Lincoln,et al. Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. , 1997, The Journal of clinical investigation.
[51] B. Gaston,et al. Nitric oxide and thiol groups. , 1999, Biochimica et biophysica acta.
[52] K. Hirata,et al. Superoxide Generation in Directional Coronary Atherectomy Specimens of Patients With Angina Pectoris: Important Role of NAD(P)H Oxidase , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[53] D. Glogar,et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. , 1997, Atherosclerosis.
[54] R. Clarke,et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.
[55] P. Durand,et al. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. , 1996, Atherosclerosis.
[56] K. Pritchard,et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[57] Newcombe,et al. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects , 1999, European journal of clinical investigation.
[58] J. Ahlner,et al. Organic nitrate esters: clinical use and mechanisms of actions. , 1991, Pharmacological reviews.
[59] G. Heusch,et al. Plasma Nitrosothiols Contribute to the Systemic Vasodilator Effects of Intravenously Applied NO: Experimental and Clinical Study on the Fate of NO in Human Blood , 2002, Circulation research.
[60] R. Brooks,et al. NO-Dependent Vasorelaxation Is Impaired After Gene Transfer of Inducible NO-Synthase , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[61] I. Mcdowell,et al. Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? , 2002, Atherosclerosis.
[62] Gabor Kaley,et al. Increased Superoxide Production in Coronary Arteries in Hyperhomocysteinemia: Role of Tumor Necrosis Factor-&agr;, NAD(P)H Oxidase, and Inducible Nitric Oxide Synthase , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[63] G. D. De Keulenaer,et al. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. , 1998, The Biochemical journal.
[64] E. Werner,et al. Tetrahydrobiopterin, Cytokines, and Nitric Oxide Synthesis 1 , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[65] T. Hagve,et al. Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. , 2001, The American journal of medicine.
[66] A. M. Lefer,et al. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion , 1991, Critical care medicine.
[67] J. Loscalzo,et al. Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase* , 1997, The Journal of Biological Chemistry.
[68] A. M. Lefer,et al. Direct measurement of nitric oxide release from vascular endothelial cells. , 1996, Journal of applied physiology.
[69] G. Hedenstierna,et al. Inhaled Nitric Oxide Selectively Reverses Human Hypoxic Pulmonary Vasoconstriction without Causing Systemic Vasodilation , 1993, Anesthesiology.
[70] B. Mayer,et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. , 2000, Circulation research.
[71] P. Aukrust,et al. Folic Acid Treatment Reduces Chemokine Release From Peripheral Blood Mononuclear Cells in Hyperhomocysteinemic Subjects , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[72] D. Harrison,et al. New insights into mechanisms underlying nitrate tolerance. , 1996, The American journal of cardiology.
[73] B. Mayer,et al. Enzymatic function of nitric oxide synthases. , 1999, Cardiovascular research.
[74] P. Tsao,et al. Homocysteine Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine , 2001, Circulation.
[75] Y. Kiuchi,et al. Presence of excess tetrahydrobiopterin during nitric oxide production from inducible nitric oxide synthase in LPS-treated rat aorta. , 1999, Life sciences.
[76] J. Stamler,et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. , 1993, The Journal of clinical investigation.
[77] P. Aukrust,et al. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects , 2003, British Journal of Nutrition.
[78] H. Morrison,et al. Serum Folate and Risk of Fatal Coronary Heart Disease , 1996 .
[79] D. Harrison,et al. Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.
[80] J. Loscalzo,et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. , 2000, The Journal of clinical investigation.
[81] S. Henning,et al. Vitamins C, E and A and heme oxygenase in rats fed methyl/folate-deficient diets. , 1997, Free Radical Biology & Medicine.
[82] E. Werner,et al. Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites. , 1996, Biochemistry.
[83] J. Loscalzo. The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.
[84] S. Moncada,et al. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor , 1986, Nature.
[85] P. Pagliaro. Regulation of basal myocardial function by NO. , 1999, Cardiovascular research.
[86] K. Woo,et al. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. , 1999, Journal of the American College of Cardiology.
[87] Z. Katusic. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? , 2001, American journal of physiology. Heart and circulatory physiology.
[88] A. M. Lefer,et al. Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide. , 1999, General pharmacology.
[89] W. Renner,et al. Vascular Dysfunction in Hyperhomocyst(e)inemia. Implications for Atherothrombotic Disease , 2001, Clinical chemistry and laboratory medicine.
[90] S. Tyagi,et al. Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. , 2002, American journal of physiology. Cell physiology.
[91] J. Higgins,et al. Folate protects against oxidative modification of human LDL , 2001, British Journal of Nutrition.
[92] J. Zweier,et al. Inducible Nitric-oxide Synthase Generates Superoxide from the Reductase Domain* , 1998, The Journal of Biological Chemistry.
[93] M. Goligorsky,et al. Effects of homocysteine on endothelial nitric oxide production. , 2000, American journal of physiology. Renal physiology.
[94] C. Nathan,et al. Inducible nitric oxide synthase: identification of amino acid residues essential for dimerization and binding of tetrahydrobiopterin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[95] S. Clarke,et al. RNA and protein interactions modulated by protein arginine methylation. , 1998, Progress in nucleic acid research and molecular biology.
[96] P. Vanhoutte,et al. The endothelium as a regulator of vascular smooth muscle proliferation , 1993 .
[97] A. M. Lefer,et al. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[98] G. Wang,et al. Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. , 2000, The Biochemical journal.
[99] P. Ueland,et al. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. , 1989, The Journal of laboratory and clinical medicine.
[100] L. Ignarro,et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[101] H P Misra,et al. Generation of superoxide free radical during the autoxidation of thiols. , 1974, The Journal of biological chemistry.
[102] R. Newcombe,et al. Folate Improves Endothelial Function in Coronary Artery Disease: An Effect Mediated by Reduction of Intracellular Superoxide? , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[103] M. Lewis,et al. The nature of endothelium-derived vascular relaxant factor , 1984, Nature.
[104] A. Hausladen,et al. Oxidative modifications in nitrosative stress , 1998, Nature Structural Biology.
[105] T. Lakka,et al. Low Dietary Folate Intake Is Associated With an Excess Incidence of Acute Coronary Events: The Kuopio Ischemic Heart Disease Risk Factor Study , 2001, Circulation.
[106] S. Tyagi,et al. Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. , 2002, American journal of physiology. Cell physiology.
[107] G. Starkebaum,et al. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. , 1986, The Journal of clinical investigation.
[108] T. Podor,et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. , 1999, Blood.
[109] S. Vollset,et al. Homocysteine and cardiovascular disease. , 1998, Annual review of medicine.
[110] P. Kubes,et al. Nitric oxide modulates microvascular permeability. , 1992, The American journal of physiology.
[111] A M Zeiher,et al. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.
[112] D. Bunout,et al. Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. , 2000, Nutrition.
[113] J. Abe,et al. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. , 1998, Trends in cardiovascular medicine.
[114] J. Kooner,et al. Improved Vascular Endothelial Function After Oral B Vitamins: An Effect Mediated Through Reduced Concentrations of Free Plasma Homocysteine , 2000, Circulation.
[115] J. Witteman,et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.
[116] T. Imaizumi,et al. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. , 1999, Clinical science.
[117] P. Tsao,et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. , 1999, Circulation.
[118] J. Kooner,et al. Hyperhomocysteinemia : An Effect Reversible With Vitamin C Therapy Demonstration of Rapid Onset Vascular Endothelial Dysfunction After , 1999 .
[119] O. Vintermyr,et al. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: Methionine loading of non‐transformed, transformed, proliferating, and quiescent cells in culture , 1991, Journal of cellular physiology.
[120] M. Lewis,et al. Endothelium Derived Relaxant Factor , 1985, Journal of the Royal College of Physicians of London.
[121] M. Creager,et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. , 1997, Circulation.
[122] E. Werner,et al. Tetrahydrobiopterin binding to macrophage inducible nitric oxide synthase: heme spin shift and dimer stabilization by the potent pterin antagonist 4-amino-tetrahydrobiopterin. , 1997, Biochemistry.
[123] S. Moncada,et al. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[124] S. Rajagopalan,et al. Altered Tetrahydrobiopterin Metabolism in Atherosclerosis: Implications for Use of Oxidized Tetrahydrobiopterin Analogues and Thiol Antioxidants , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[125] H. Blom,et al. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials , 1998, BMJ.
[126] D. Harrison,et al. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.
[127] M. S. Katz,et al. EGF inhibits muscarinic receptor-mediated calcium signaling in a human salivary cell line. , 2000, American journal of physiology. Cell physiology.
[128] A. M. Lefer,et al. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. , 1996, Circulation research.
[129] J. Kastelein,et al. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. , 1998, Circulation.
[130] K. Woo,et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. , 1997, Circulation.
[131] B. Mayer,et al. A synthetic peptide corresponding to the putative dihydrofolate reductase domain of nitric oxide synthase inhibits uncoupled NADPH oxidation. , 1997, Nitric oxide : biology and chemistry.
[132] S. Hernández-Díaz,et al. Dietary Folate and the Risk of Nonfatal Myocardial Infarction , 2002, Epidemiology.